NCT06005870 Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
| NCT ID | NCT06005870 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Huazhong University of Science and Technology |
| Condition | Diffuse Large B Cell Lymphoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 41 participants |
| Start Date | 2022-11-26 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 41 participants in total. It began in 2022-11-26 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aim to evaluate the efficacy and safety of zanubrutinib combined with R-CHOP in the treatment of DLBCL patients with p53 protein expression.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years, ≤ 75 years, both sexes; 2. Diff use large B-cell lymphoma diagnosed by histopathology without previous systemic DLBCL treatment; 3. ECOG score: 0-2; 4. Predicted survival ≥3 months; 5. Patients with positive p53 expression detected by immunohistochemistry (≥50% ); 6. The patients had certain conditions of organ function reserve, and the laboratory tests within 1 week before enrollment met the following conditions: Blood routine: neutrophil count (NEUT) ≥1.5×10\^9/L, platelet count (PLT) ≥75×10\^9/L, hemoglobin (HGB) ≥80 g/L; G-CSF was not used in the past 7 days (the researchers judged that the lymphoma-induced cytopenia could be included). Liver function: Total bilirubin (TBIL) ≤1.5× upper limit of the normal range (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; If liver metastases were present, TBIL≤3×ULN, ALT and AST≤5×ULN; Renal function: serum creatinine (Cr) ≤2.0×ULN or creatinine clearance (CCr) ≥60ml/min; Cardiac function: LVEF≥50%, ECG did not indicate any acute myocardial infarction, arrhythmia, or atrioventricular conduction block above grade I; Thyroid function: thyroid stimulating hormone (TSH) was within the normal range. If TSH is abnormal, free triiodothyronine (FT3) and free thyroxine (FT4) should be within the normal range or abnormal without clinical significance. 1. According to the Lugano2014 assessment criteria, patients must have measurable lesions, defined as the longest diameter of at least one nodule \> 1.5cm, or the longest diameter of at least one nodule \> 1cm, and at least two vertical diameters that can be accurately measured. 2. Patients volunteered to participate in the trial, understood the study procedure, and were able to sign in-person informed consent. Exclusion Criteria: 1. Patients with definite lymphoma central nervous system (CNS) infiltration, including brain parenchyma, meningeal invasion, or spinal cord compression; 2. severe or uncontrolled infection; 3. with active autoimmune disease; 4. Other serious medical conditions, such as uncontrolled diabetes, gastric ulcers, other serious cardiopulmonary diseases, etc. (the decision was left to the investigator); 5. patients who received the live attenuated vaccine within 4 weeks before the first dose or planned to receive the live attenuated vaccine during the study; 6. The subject has previous or co -e xis ting other malignant tumors; Patients with basal cell carcinoma of the skin and uterine and neck carcinoma in situ who had been cured for more than 3 years, and patients with other malignant tumors who had been cured for more than 5 years were considered for inclusion. 7. HIV-positive patients with active hepatitis B ( HBV-DNA \> 100 copies/m L), positive HCV antibody, or abnormal HCV-RNA 8. Women who were pregnant or lactating, women who planned to become pregnant between the study period and 6 months after the last dose, or men whose partners planned to become pregnant, who were unwilling to use a medically approve defective contraceptive method (e.g., intrauterine device or condom ) during the trial; 9. were allergic to any of the drugs in the study protocol; 10. ineligible for inclusion as judged by the investigator ;
Contact & Investigator
Liling Zhang, M.D
STUDY CHAIR
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Frequently Asked Questions
Who can join the NCT06005870 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Diffuse Large B Cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06005870 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06005870 currently recruiting?
Yes, NCT06005870 is actively recruiting participants. Contact the research team at lily1228@sina.com for enrollment information.
Where is the NCT06005870 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT06005870 clinical trial?
NCT06005870 is sponsored by Huazhong University of Science and Technology. The principal investigator is Liling Zhang, M.D at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. The trial plans to enroll 41 participants.